The Ontario Neurodegenerative Disease Research Initiative

Objective: In individuals over the age of 65, concomitant neurodegenerative pathologies contribute to cognitive and/or motor decline and can be aggravated by cerebrovascular disease, but our understanding of how these pathologies synergize to produce the decline represents an important knowledge gap. The Ontario Neurodegenerative Disease Research Initiative (ONDRI), a multi-site, longitudinal, observational cohort study, recruited participants across multiple prevalent neurodegenerative diseases and cerebrovascular disease, collecting a wide array of data and thus allowing for deep investigation into common and unique phenotypes. This paper describes baseline features of the ONDRI cohort, understanding of which is essential when conducting analyses or interpreting results. Methods: Five disease cohorts were recruited: Alzheimer's disease/amnestic mild cognitive impairment (AD/MCI), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson's disease (PD), and cerebrovascular disease (CVD). Assessment platforms included clinical, neuropsychology, eye tracking, gait and balance, neuroimaging, retinal imaging, genomics, and pathology. We describe recruitment, data collection, and data curation protocols, and provide a summary of ONDRI baseline characteristics. Results: 520 participants were enrolled. Most participants were in the early stages of disease progression. Participants had a median age of 69 years, a median Montreal Cognitive Assessment score of 25, a median percent of independence of 100 for basic activities of daily living, and a median of 93 for instrumental activities. Variation between disease cohorts existed for age, level of cognition, and geographic location. Conclusion: ONDRI data will enable exploration into unique and shared pathological mechanisms contributing to cognitive and motor decline across the spectrum of neurodegenerative diseases.

[1]  S. Strother,et al.  The Quality Assurance and Quality Control Protocol for Neuropsychological Data Collection and Curation in the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study , 2020, Assessment.

[2]  Corinne E. Fischer,et al.  Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer’s Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years , 2020, Journal of Alzheimer's disease : JAD.

[3]  Stephen C. Strother,et al.  An overview of the quality assurance and quality control of magnetic resonance imaging data for the Ontario Neurodegenerative Disease Research Initiative (ONDRI): pipeline development and neuroinformatics , 2020, bioRxiv.

[4]  Seyyed M H Haddad,et al.  Comparison of quality control methods for automated diffusion tensor imaging analysis pipelines , 2019, PloS one.

[5]  Melissa F. Holmes,et al.  Ontario Neurodegenerative Disease Research Initiative (ONDRI): Structural MRI methods & outcome measures , 2019, bioRxiv.

[6]  D. Stuss,et al.  APOE ε4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia , 2019, Neurology.

[7]  Bryan M. Wong,et al.  Validation of Optical Coherence Tomography Retinal Segmentation in Neurodegenerative Disease , 2019, Translational vision science & technology.

[8]  Lorne Zinman,et al.  The utility of multivariate outlier detection techniques for data quality evaluation in large studies: an application within the ONDRI project , 2019, BMC Medical Research Methodology.

[9]  Maxime Descoteaux,et al.  The Canadian Dementia Imaging Protocol: Harmonizing National Cohorts , 2018, Journal of magnetic resonance imaging : JMRI.

[10]  Norbert Schuff,et al.  The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort , 2018, Annals of clinical and translational neurology.

[11]  S. Love,et al.  A broader view of dementia: multiple co-pathologies are the norm. , 2018, Brain : a journal of neurology.

[12]  Stephen C. Strother,et al.  Generalization of the minimum covariance determinant algorithm for categorical and mixed data types , 2018, bioRxiv.

[13]  Stephen C. Strother,et al.  Brain-CODE: A Secure Neuroinformatics Platform for Management, Federation, Sharing and Analysis of Multi-Dimensional Neuroscience Data , 2018, Front. Neuroinform..

[14]  Ming Zhang,et al.  Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease , 2018, Journal of visualized experiments : JoVE.

[15]  Angus Silver,et al.  NeuroMatic: An Integrated Open-Source Software Toolkit for Acquisition, Analysis and Simulation of Electrophysiological Data , 2018, Front. Neuroinform..

[16]  Norbert Schuff,et al.  Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort , 2018, Movement disorders : official journal of the Movement Disorder Society.

[17]  Dimo Ivanov,et al.  Determining Excitatory and Inhibitory Neuronal Activity from Multimodal fMRI Data Using a Generative Hemodynamic Model , 2017, Front. Neurosci..

[18]  N. Greig,et al.  Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview. , 2017, Current Alzheimer research.

[19]  D. Aarsland,et al.  Maximizing the Potential of Longitudinal Cohorts for Research in Neurodegenerative Diseases: A Community Perspective , 2017, Front. Neurosci..

[20]  D. Krewski,et al.  Burden of neurological conditions in Canada , 2017, Neurotoxicology.

[21]  Douglas P. Munoz,et al.  Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI) , 2017, Journal of Alzheimer's disease : JAD.

[22]  Lorne Zinman,et al.  The Ontario Neurodegenerative Disease Research Initiative (ONDRI) , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[23]  John F. Robinson,et al.  The ONDRISeq panel: custom-designed next-generation sequencing of genes related to neurodegeneration , 2016, npj Genomic Medicine.

[24]  Yee-Hong Yang,et al.  Cerebral Degeneration in Amyotrophic Lateral Sclerosis Revealed by 3-Dimensional Texture Analysis , 2016, Front. Neurosci..

[25]  L. Clare,et al.  Cognitive reserve and cognitive function in healthy older people: a meta-analysis , 2016, Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.

[26]  Arthur W. Toga,et al.  Sharing data in the global alzheimer's association interactive network , 2016, NeuroImage.

[27]  C. Belden,et al.  Age- and education-adjusted normative data for the Montreal Cognitive Assessment (MoCA) in older adults age 70–99 , 2015, Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.

[28]  Veronica Redaelli,et al.  Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis , 2015, The Lancet Neurology.

[29]  M. Borrie,et al.  Primary Care–Based Memory Clinics: Expanding Capacity for Dementia Care* , 2014, Canadian Journal on Aging / La Revue canadienne du vieillissement.

[30]  Isabelle Vedel,et al.  Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: recommendations for family physicians. , 2014, Canadian family physician Medecin de famille canadien.

[31]  Nick C Fox,et al.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration , 2013, The Lancet Neurology.

[32]  Cheryl Cook,et al.  Knowledge translation: an overview and recommendations in relation to the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia , 2013, Alzheimer's Research & Therapy.

[33]  O. Hardiman,et al.  Cognitive changes predict functional decline in ALS , 2013, Neurology.

[34]  Mark Hallett,et al.  Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.

[35]  J. Karlawish,et al.  Are Patients Whose Study Partners Are Spouses More Likely to be Eligible for Alzheimer’s Disease Clinical Trials , 2012, Dementia and Geriatric Cognitive Disorders.

[36]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[37]  J. Perlmutter,et al.  Neurologist care in Parkinson disease , 2011, Neurology.

[38]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[39]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[40]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[41]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.

[42]  K. Huybrechts,et al.  The Prognostic Value of the Modified Rankin Scale Score for Long-Term Survival after First-Ever Stroke , 2008, Cerebrovascular Diseases.

[43]  David A. Bennett,et al.  Mixed brain pathologies account for most dementia cases in community-dwelling older persons , 2007, Neurology.

[44]  F. Murtagh Multiple correspondence analysis and related methods , 2007 .

[45]  M. Greenacre,et al.  Multiple Correspondence Analysis and Related Methods , 2006 .

[46]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[47]  M. Naumann,et al.  Disease progression in amyotrophic lateral sclerosis: Predictors of survival , 2002, Muscle & nerve.

[48]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[49]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.